Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in COVID-19
NCT04304313Phase 3Unknown
- Sponsor
- Tongji Hospital
- Start
- Feb 2020
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sildenafil in coronavirus disease 2019 (COVID-19), sponsored by Tongji Hospital. Primary endpoints: Rate of disease remission at 14 days, Rate of entering the critical stage at 14 days and 1 more. Status: unknown.
02
Drugs
sildenafil
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04304313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304313.